|
Market Cap (24-Jun) $7,649,007 (1,598th) |
Close (30-Jun) $0.024 |
Volume (30-Jun) 2,170,184 |
Shortsold (2-Feb) 3,141 (0.00%) (662nd) |
|
52w High $0.008 |
52w Low $0.002 |
P/E - |
EPS 0 |
1AD released this announcement to the ASX on 24 February 2021, 8:16. The announcement is marked as price sensitive, and is 2 page(s) in length and 285.62kb in size.
You can view all announcements from 1AD and see how they appear on a price chart on the announcements page.
| Other Recent Announcements from 1AD | |
|---|---|
| AD-214 clinical trial approval | 29 June 2023, 8:21 |
| Change in substantial holding | 31 May 2023, 13:30 |
| Change in substantial holding | 31 May 2023, 9:34 |
| FDA Orphan Drug Designation for AD-214 | 24 February 2021, 8:16 |
| Quarterly Appendix 4C and Activities Report | 28 January 2021, 16:32 |
| Phase I HV extension to explore encouraging results | 14 December 2020, 10:12 |
| Change of Director's Interest Notice | 30 November 2020, 8:52 |
You must be logged in to post a reply.
AdAlta 